Patents on novel compounds and processes, Section 3(d) and 3(j) considerations, trademark Class 1, hazard-classification and trade-secret protection. Indian chemicals is a patent-heavy IP sector.
Indian chemicals — Tata Chemicals, UPL, Pidilite, Asian Paints, Hikal, SRF, Aarti Industries, Deepak Nitrite — is one of the largest patent-filing sectors in the country. Compound patents, process patents, formulation patents, application-specific patents all sit alongside trademark filings on the commercial brand, design registrations on distinctive packaging, and substantial trade-secret protection on manufacturing know-how. The Patents Act subject-matter exclusions — Section 3(d), 3(j), 3(p) — interact with chemical patent prosecution in distinctive ways, and the operational IP file integrates patent strategy with regulatory compliance (CIB, FCO, REACH for EU exports).
For Indian chemical companies — specialty, fine, agrochemical, paint, adhesive, dye — the IP file decides what gets patented, what stays in trade secret, and how the company defends against close-imitation product launches by competitors.
Three filings cover most of the IP risk on day one. Each is a standalone service and each links to a deeper walkthrough.
Indian chemical patents file across several distinct claim categories:
Indian chemical patent prosecution navigates Section 3(d) (incremental forms without enhanced efficacy excluded), Section 3(b) (inventions contrary to public order or morality), and Section 3(p) (traditional knowledge excluded). For agrochemicals specifically, Section 3(h) excludes methods of agriculture or horticulture.
The principal classes:
Specialty chemical brands typically file in 2-4 classes depending on the product range. Industrial-chemicals B2B brands often combine Class 1 with the application-specific class (Class 2 for coatings, Class 5 for pharma intermediates).
Indian chemical companies rely heavily on trade-secret protection for manufacturing processes that are difficult to reverse-engineer from the final product. The framework is the standard Indian trade-secret stack — employee assignment, vendor NDAs, manufacturing-contractor confidentiality, operational access controls.
For specialty chemical companies, the choice between patenting (full disclosure but 20-year monopoly) and trade-secret (indefinite protection but vulnerable to reverse engineering and independent invention) is strategic. Processes that are difficult to reverse-engineer often stay as trade secret; compounds and formulations more easily identifiable through analysis go through the patent route.
Chemical products face multiple regulatory regimes that require disclosure of composition or process details:
The sequencing matters — patent filings should typically precede regulatory submissions to preserve novelty. Disclosed information in regulatory filings can become prior art that defeats subsequent patent applications.
Indian chemical companies with international markets typically file through the PCT system. National-phase entry into major markets (US, EU, China, Japan) is the standard global protection strategy. Cross-border licensing and joint-development agreements — common in Indian specialty chemicals — require careful IP allocation between the Indian and foreign partners.
Chemical company building patent portfolio, navigating Section 3(d), managing trade secrets? The IP file integrates with the regulatory file. Send us the product range.
WhatsApp our team →Section 3(d) excludes 'new forms of a known substance which do not result in enhancement of known efficacy' — typically applied to pharma but applicable to chemical compounds generally. Incremental polymorphs, salts, isomers without demonstrated enhanced efficacy fail Section 3(d). New compounds and genuinely novel formulations remain patentable.
Class 1 (industrial chemicals) is primary. Add Class 2 (paints, coatings), Class 3 (cleaning preparations), Class 5 (pharmaceutical intermediates), Class 16 (adhesives), Class 35 (retail/trading). Most specialty chemical brands file in 2-4 classes covering their product range.
Depends on reverse-engineering difficulty. Processes that are difficult to reverse-engineer from the final product often stay as trade secret (indefinite protection). Compounds and formulations more easily analysed are typically patented (20-year monopoly with full disclosure). The strategic choice is product-specific.
Yes. Patent applications should be filed before any regulatory submission that discloses inventive subject matter. Information disclosed in CIB, FCO or similar regulatory filings can become prior art that defeats subsequent patent applications under Section 13(1)(b) novelty.